VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Vertex (VERX) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts ...

SurgeGraph, one of the leading AI writing tools, today announced the launch of SurgeGraph Vertex, featuring its latest ...

Tool Live In The Sand will take place at the Hard Rock Hotel in Punta Cana, Dominican Republic from March 7 - 9 2025 When you purchase through links on our site, we may earn an affiliate commission.

Vertex Pharmaceuticals is in the process of getting a new painkiller approved. It just published some data that suggests the candidate will be quite profitable. But regulators still need to sign ...

Tool have just announced Live in the Sand, their very own destination festival taking place in 2025 with an impressive lineup. The three-day event will be include a five-star all-inclusive ...

So when a business like Vertex Pharmaceuticals (NASDAQ: VRTX) releases some new data on a potential blockbuster that could be just a few months away from being approved for sale, it's a big ...

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...

Aside from the positive safety data, Vertex also reported an efficacy update for suzetrigine at ASA 2024. In abdominoplasty patients, suzetrigine monotherapy led to a 48.4-point improvement in pain ...

If you plan on repairing or maintaining your motorcycle at home, you're going to want a solid motorcycle tool kit at the ready. That means a kit that not only includes all of the tools you'll ...

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex ...